Capital One Initiates Coverage On EyePoint Pharmaceuticals with Overweight Rating, Announces Price Target of $44
Portfolio Pulse from Benzinga Newsdesk
Capital One analyst Zegbeh Jallah has initiated coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT) with an Overweight rating and set a price target of $44.
December 11, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EyePoint Pharmaceuticals received an Overweight rating from Capital One with a price target of $44, indicating a positive outlook from the analyst.
The initiation of coverage by Capital One with an Overweight rating and a price target significantly higher than the current trading price is likely to be viewed positively by investors. This could lead to increased investor confidence and a potential short-term rise in the stock price of EyePoint Pharmaceuticals.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100